Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Small Cell Lung Cancer
- Registration Number
- NCT00316433
- Lead Sponsor
- Swedish Medical Center
- Brief Summary
The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Previously untreated extensive small cell lung cancer
- No prior chemotherapy
- No prior radiotherapy except for the treatment of brain metastases
Exclusion Criteria
- Prior treatment for extensive stage small cell lung cancer
- Known hypersensitivity to any of the components of oxaliplatin or CPT-11
- Greater than grade 2 peripheral neuropathy
- Known HIV or Hepatitis B or C (active, previously treated or both)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Swedish Medical Center Cancer Institute
🇺🇸Seattle, Washington, United States